Dr. Singh’s research builds upon her mentors’ previous work using multiplex digital methylation-specific PCR platform in the simultaneous analysis of four methylation biomarkers (SOX17, TAC1, CDL1, HOXA7) for liquid-biopsy-based detection of lung cancer. Dr. Singh is currently developing a cohort of patients within the Veteran Affairs Pittsburgh Health System population undergoing low dose computed tomography (CT) based lung cancer screening. Those who are found to have indeterminate pulmonary nodules (LungRADS >3 or equivalent) will be recruited for this study. Using the collected samples, she will perform the above methylation specific PCR for the above genes on blood and bronchoalveolar lavage samples from these patients. These patients will be followed over a two-year period for the development of lung cancer. She has obtained IRB approval for the study and has begun the recruiting process with an estimate of 550 Veterans being enrolled in this study over her T32 support period.
- BS, Biology, St. Bonaventure University, 2013
- MS, Radiation Biology, University of Oxford, 2014
- MD, George Washington University School of Medicine and Health Sciences, 2018
- Residency, Internal Medicine, University of Pittsburgh School of Medicine, 2022
- Fellowship, Pulmonary and Critical Care Medicine, University of Pittsburgh School of Medicine, 2025
